BLB&B Advisors LLC Has $214,000 Stock Holdings in Cencora, Inc. $COR

BLB&B Advisors LLC cut its holdings in Cencora, Inc. (NYSE:COR) by 12.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 715 shares of the company’s stock after selling 100 shares during the quarter. BLB&B Advisors LLC’s holdings in Cencora were worth $214,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of COR. Atlantic Edge Private Wealth Management LLC lifted its position in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC grew its position in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after purchasing an additional 48 shares in the last quarter. Costello Asset Management INC acquired a new stake in Cencora in the 1st quarter valued at $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the 1st quarter worth about $39,000. Finally, Olde Wealth Management LLC acquired a new position in shares of Cencora during the 1st quarter worth about $48,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by company insiders.

Cencora Trading Down 1.1%

NYSE COR opened at $337.60 on Friday. The company has a market cap of $65.45 billion, a PE ratio of 34.73, a PEG ratio of 1.56 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $350.46. The stock has a 50 day moving average of $308.09 and a 200-day moving average of $297.02.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter in the prior year, the firm posted $3.34 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio is 22.63%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on COR shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Evercore ISI set a $340.00 price target on Cencora in a research report on Wednesday, October 8th. UBS Group increased their price objective on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a report on Monday. Finally, Wells Fargo & Company increased their price objective on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $329.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.